TipRanks

Notifications

Tag: MRK

Total 590 Posts

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Shockwave Medical (SWAV) and Korro Bio (KRRO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merck & Company (MRKResearch Report), Shockwave Medical (SWAVResearch Report) and Korro Bio (KRROResearch Report) with bullish sentiments.

Merck & Company (MRK)

TD Cowen analyst Steve Scala maintained a Buy rating on Merck & Company today and set a price target of $135.00. The company’s shares closed last Tuesday at $125.52, close to its 52-week high of $130.24.

According to TipRanks.com, Scala is a 4-star analyst with an average return of 9.0% and a 66.7% success rate. Scala covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, AstraZeneca, and Novartis.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Merck & Company with a $134.59 average price target, a 7.0% upside from current levels. In a report issued on March 18, Bank of America Securities also maintained a Buy rating on the stock with a $135.00 price target.

See today’s best-performing stocks on TipRanks >>

Shockwave Medical (SWAV)

Piper Sandler analyst Adam Maeder maintained a Buy rating on Shockwave Medical today and set a price target of $290.00. The company’s shares closed last Tuesday at $316.07, close to its 52-week high of $327.73.

According to TipRanks.com, Maeder is a 5-star analyst with an average return of 21.3% and a 61.5% success rate. Maeder covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Intuitive Surgical.

Currently, the analyst consensus on Shockwave Medical is a Moderate Buy with an average price target of $253.29, representing a -12.0% downside. In a report issued on March 19, Bank of America Securities also reiterated a Buy rating on the stock with a $310.00 price target.

Korro Bio (KRRO)

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Korro Bio today and set a price target of $180.00. The company’s shares closed last Tuesday at $86.95, close to its 52-week high of $89.00.

According to TipRanks.com, Rahimi is a 4-star analyst with an average return of 8.2% and a 38.0% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, NewAmsterdam Pharma Company, and Praxis Precision Medicines.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Korro Bio with a $122.50 average price target, which is a 67.6% upside from current levels. In a report issued on March 12, RBC Capital also maintained a Buy rating on the stock with a $70.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MRK:

Wells Fargo העלו את מחיר היעד שלהם עבור Merck ל-135 ליש”ט מהמחיר הקודם של 130 ליש”ט וממשיכים להמליץ על החזקת המניות

Wells Fargo העלו את מחיר היעד שלהם עבור Merck ל-135 ליש”ט מהמחיר הקודם של 130 ליש”ט וממשיכים להמליץ על החזקת המניות. הם מציינים כי WINREVAIR, הידוע גם כסוטטרספט, קיבל אישור